445例药物性肝损伤的临床分析

朱春雾; 王海南; 袁继丽; 彭渊; 张亚蕾; 薛冬英; 张琴; 刘成海

doi:10.3969/j.issn.1001-5256.2018.02.027

445例药物性肝损伤的临床分析

DOI: 10.3969/j.issn.1001-5256.2018.02.027

1. 上海中医药大学附属曙光医院肝病研究所
2. 国家食品药品监督管理总局
3. 上海中医药大学附属普陀医院感染科
4. 上海交通大学医学院附属同仁医院感染科
5. 上海市中医临床重点实验室
6. 上海市高校中医内科学E研究院

基金项目:

上海市三年行动计划(ZY3-CCCX-2-1003)；

详细信息

中图分类号: R575
计量
- 文章访问数: 2572
- HTML全文浏览量: 103
- PDF下载量: 595
- 被引次数: 48
出版历程
- 出版日期: 2018-02-20

Clinical features of drug-induced liver injury: an analysis of 445 cases

Institute of Hepatology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Research funding:

摘要

摘要:
目的描述性分析药物性肝损伤（DILI）的临床特征。方法回顾性收集2012年1月-2016年12月在上海中医药大学附属曙光医院、上海中医药大学附属普陀医院、上海交通大学医学院附属同仁医院诊断为DILI的445例患者的病史、症状体征、检查结果、治疗与转归等临床资料,分析DILI的临床特征。计量资料以中位数和四分位数间距[M（P25P75）]表示,组间比较采用Kruskal-Wallis H检验;计数资料组间比较采用χ2检验。结果 445例患者中,男136例（30.56%）,女309例（69.44%）,以4069岁的人群居多。194例（43.6%）应用西药导致,140例（31.46%）应用中药导致,中西药联用者92例（20.67%）,服用保健品者19例（4.27%）。引起肝损伤的中药主要有何首乌及其制剂、仙灵骨葆胶囊、癃闭舒胶囊等;导致肝损伤的西药主要有心血管用药、抗微生物用药、解热镇痛药、抗肿瘤用药、抗结核药等。临床症状主要有乏力、纳差、黄疸、恶心等,其中以乏力（65.17%）最常见。临床分型主要为肝细胞损伤型,占70.11...
- 药物性肝损伤 /
- 体征和症状
Abstract:
Objective To investigate the clinical features of drug-induced liver injury (DILI) by descriptive analysis.Methods A retrospective analysis was performed for the clinical data of 445 patients who were diagnosed with DILI in Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Putuo Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, and Tongren Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from January 2012 to December 2016, including medical history, signs and symptoms, examination results, treatment, and prognosis.The clinical features of DILI were analyzed.The continuous data were expressed as median and inter-quartile range M (P25-P75) , and the Kruskal-Wallis H test was used for comparison of continuous data between groups; the chi-square test was used for comparison of categorical data between groups.Results Among all 445 patients, there were 136 male patients (30.56%) and 309 female patients (69.44%) , and most of the patients were aged 40-69 years.Of all patients, 194 (43.6%) had DILI induced by Western medicine, 140 (31.46%) had DILI induced by traditional Chinese medicine, 92 (20.67%) had DILI induced by Western medicine and traditional Chinese medicine, and 19 (4.27%) had DILI induced by healthcare products.Traditional Chinese medicine which induced DILI included Fallopia multiflora and its preparation, Xianling Gubao capsules, and Longbishu capsules, and Western medicine which induced DILI included cardiovascular drugs, antimicrobial agents, antipyretic and analgesic drugs, antitumor drugs, and antitubercular agents.Major clinical symptoms included weakness, poor appetite, jaundice, and nausea, among which weakness was the most common symptom, seen in 65.17% of all patients.Of all patients, 70.11% had hepatocellular injury type.There were significant differences in peak values of alanine aminotransferase (ALT) , aspartate aminotransferase (AST) , alkaline phosphatase, total bilirubin (TBil) , and international normalized ratio between patients with different types of DILI (t = 153.584, 97.366, 27.781, 24.177 and 6.236, all P < 0.05) , and the patients with liver injury induced by traditional Chinese medicine had significantly higher peak values of ALT, AST, and TBil than those with liver injury induced by Western medicine (all P < 0.05) .There was significant differences in liver injury score between patients with different types of DILI (χ2= 26.848, P < 0.001) .Of all patients, 98.65% achieved improvement, and there was no significant difference in prognosis between the patients with liver injury induced by traditional Chinese medicine and those with liver injury induced by Western medicine (χ2= 3.663, P > 0.05) .Conclusion DILI is commonly seen in female patients and middle-aged and elderly patients.Compared with those with liver injury induced by Western medicine, the patients with liver injury induced by traditional Chinese medicine have significantly greater abnormalities of biochemical parameters.Most of the patients with DILI have good prognosis.
- drug-induced liver injury /
- signs and symptoms

HTML全文

参考文献(12)

[1]Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association.Guidelines for the management of drug-induced liver injury[J].J Clin Hepatol, 2015, 31 (11) :1752-1769. (in Chinese) 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].临床肝胆病杂志, 2015, 31 (11) :1752-1769.

[2]CHEN M, SUZUKI A, BORLAK J, et al.Drug-induced liver injury:interactions between drug properties and host factors[J].J Hepatol, 2015, 63 (2) :503-514.

[3]DAVID S, HAMILTON JP.Drug-induced liver injury[J].US Gastroenterol Hepatol Rev, 2010, 6:73-80.

[4]BENICHOU C.Criteria of drug-induced liver disorders[J].J Hepatol, 1990, 11 (2) :272-276.

[5]CHALASANI N, BONKOVSKY HL, FONTANA R, et al.Features and outcomes of 889 patients with drug-induced liver injury:the DILIN prospective study[J].Gastroenterology, 2015, 148 (7) :1340-1352.

[6]ZHANG RX.The warning of the increased incidence of cardiovascular and cerebrovascular disease[J].Chin J Libr Inform Sci Tradit Chin Med, 2014, 38 (1) :30-31. (in Chinese) 张瑞祥.心脑血管病发病率上升的警示[J].中国中医药图书情报杂志, 2014, 38 (1) :30-31.

[7]REN ZQ, WANG JH, GUO XY, et al.A review analysis of Chinese literatures 2005-2014:clinical features of drug-induced liver injury[J].Chin J harmacoepidemiol, 2016, 25 (5) :284-289. (in Chinese) 任张青, 王进海, 郭晓燕, 等.2005~2014年我国药物性肝损伤临床综合分析[J].药物流行病学杂志, 2016, 25 (5) :284-289.

[8]ZHOU Y, YANG L, LIAO Z, et al.Epidemiology of drug-induced liver injury in China:a systematic analysis of the Chinese literature including 21, 789 patients[J].Eur J Gastroenterol Hepatol, 2013, 25 (7) :825-829.

[9]HU Q, LIU W, SHAO H.Research progress of pharmacotherapy drug-induced liver injury[J].Chin J Clin Pharmacol Ther, 2016, 21 (2) :231-236. (in Chinese) 胡琴, 刘维, 邵宏.药物性肝损伤的药物治疗研究进展[J].中国临床药理学与治疗学, 2016, 21 (2) :231-236.

[10]ANTOINE DJ, DEAR JW, LEWIS PS, et al.Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital[J].Hepatology, 2013, 58 (2) :777-787.

[11]NICOLETTI P, AITHAL GP, BJORNSSON ES, et al.Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in hla and other genes in a Genome-Wide Association study[J].Gastroenterology, 2017, 152 (5) :1078-1089.

[12]CHEN M, BORLAK J, TONG W.A model to predict severity of drug-induced liver injury in humans[J].Hepatology, 2016, 64 (3) :931-940.

施引文献

期刊类型引用(37)

1.	李容容，苟悦，刘宁宁，陈日润，孙鑫，刘成海. 基于临床数据挖掘的中药对抗肿瘤药物相关肝损伤的影响及用药规律探讨. 时珍国医国药. 2024(01): 243-247 . 百度学术
2.	张倩茹，卢颖，张婉婷，杨艳. 某院急性白血病患者药源性肝损伤临床治疗的回顾性分析. 遵义医科大学学报. 2024(04): 401-407 . 百度学术
3.	中华医学会，中华医学会杂志社，中华医学会肝病分会药物性肝病学组，中华医学会全科医学分会，中华医学会《中华全科医师杂志》编辑委员会，中国医药生物技术协会药物性肝损伤防治技术专业委员会，中国初级卫生保健基金会药物肝脏安全性专业委员会，中国药物性肝损伤基层诊疗与管理指南制定专家组. 中国药物性肝损伤基层诊疗与管理指南(2024年). 中华全科医师杂志. 2024(08): 813-830 . 百度学术
4.	郑晖，孙蓉. 药物联合应用对中草药相关肝损伤的影响. 临床肝胆病杂志. 2024(08): 1519-1524 . 本站查看
5.	李容容，李盟，苟悦，罗琼，吕桦，孙鑫，刘成海. 113例抗肿瘤药物相关肝损伤的临床特点及危险因素分析. 中国药物警戒. 2023(05): 505-510 . 百度学术
6.	中国医药生物技术协会药物性肝损伤防治技术专业委员会，中华医学会肝病学分会药物性肝病学组. 中国药物性肝损伤诊治指南(2023年版). 中华肝脏病杂志. 2023(04): 355-384 . 百度学术
7.	程诗思，杨成明，曾安津. 荆州地区结核病专科医院抗结核药物不良反应分析. 临床合理用药. 2023(22): 147-150 . 百度学术
8.	江程，李春晓，杨玉晴，郭静. 热毒宁注射液上市后临床安全性文献研究. 中国药事. 2023(11): 1252-1265 . 百度学术
9.	王双双，熊清芳，胡一帆，陈妙洋，杨永峰. 药物性肝损伤的临床与病理特点分析. 肝脏. 2023(11): 1280-1284 . 百度学术
10.	孟尧，张萌萌，郭甜甜，赵新颜. 《中国药物性肝损伤诊治指南（2023年版）》更新要点解读. 中国肝脏病杂志(电子版). 2023(04): 1-5 . 百度学术
11.	马世武，刘成海，刘晓琰，苏明华，李东良，李异玲，陈公英，陈军，陈金军，茅益民，赵景民，郭晓燕，唐洁婷，诸葛宇征，谢青，谢雯，赖荣陶，蔡大川，蔡庆贤. 中国药物性肝损伤诊治指南（2023年版）. 胃肠病学. 2023(07): 397-431 . 百度学术
12.	孙晓楠，吕萌，程国亭. 药物性肝损伤139例回顾性分析. 中南医学科学杂志. 2022(03): 391-394 . 百度学术
13.	李娜. 肺癌患者化疗后药物性肝损伤的临床特点. 中国医药指南. 2022(16): 22-25 . 百度学术
14.	劳明珠. 异甘草酸镁治疗抗肿瘤药物引起的急性药物性肝损伤临床效果和安全性. 临床合理用药杂志. 2022(17): 84-87 . 百度学术
15.	马万龙，焦运，张旭，丁向春，张平，欧阳花，王梦甜，张乐，徐灵博，杨安宁，姜怡邓. 血清IL-6在人工肝治疗药物性肝损伤预后评估中的价值. 宁夏医科大学学报. 2022(06): 622-629 . 百度学术
16.	沈婷婷，李光耀，罗琼，李盟，孙鑫，陶艳艳，周祖山，刘成海. 类风湿性关节炎患者应用雷公藤制剂及合并用药所致药物性肝损伤的临床特征分析. 临床肝胆病杂志. 2022(09): 2067-2072 . 本站查看
17.	马世武，刘成海，刘晓琰，苏明华，李东良，李异玲，陈公英，陈军，陈金军，茅益民，赵景民，郭晓燕，唐洁婷，诸葛宇征，谢青，谢雯，赖荣陶，蔡大川，蔡庆贤. 中国药物性肝损伤诊治指南（2023年版）. 胃肠病学. 2022(06): 341-375 . 百度学术
18.	汪涛，王学伟，蒋元烨，曹勤，季光. 162例药物性肝损伤患者分析. 肝脏. 2021(03): 243-246 . 百度学术
19.	王艳，王昱，王岚，田秋菊，杨瑞园，李柯鑫，刘立伟，王晓明，王宇，欧晓娟，贾继东，赵新颜. 中草药与西药致药物性肝损伤的临床特征及其预后的对比研究. 肝脏. 2021(04): 364-369 . 百度学术
20.	杨焕芝，李兴德，陈学平，张仲安，钱彦华，蒋潇，徐艳琼，宋沧桑. 93例药物性肝损伤患者临床特征分析. 中国药业. 2021(15): 122-125 . 百度学术
21.	何婷婷，王丽苹，任璐彤，崔延飞，柏兆方，郭玉明，宫嫚，王睿林. 中西药肝损伤临床及病理特征分析. 肝脏. 2021(09): 962-967 . 百度学术
22.	刘秀兰，李为，郭敏，杜金凤，刘东，李娟. 药物性肝损伤相关医疗损害案例分析. 药物流行病学杂志. 2021(11): 729-734 . 百度学术
23.	陈凯霞，赵广玉，印登阳，陈宏俊，黄继勋. 三种保肝药治疗化疗引起的DILI的药物经济学评价. 中国实用医药. 2021(35): 188-191 . 百度学术
24.	罗琼，朱哿瑞，顾宏图，刘坤，陈高峰，邢枫，陶艳艳，刘成海. 50例中草药与西药致药物性肝损伤患者的肝组织病理学特点比较. 临床肝胆病杂志. 2020(03): 596-601 . 本站查看
25.	蔡春梅. 妊娠早期肝功能异常60例的病因分析及干预. 中国城乡企业卫生. 2020(06): 100-102 . 百度学术
26.	周力. 中西药所致药物性肝损伤临床及病理特点研究. 临床医药文献电子杂志. 2020(39): 56 . 百度学术
27.	纪童童，陆海英，谭宁，于岩岩，徐小元. 急、慢性药物性肝损伤临床特征的对比分析. 临床肝胆病杂志. 2020(07): 1556-1561 . 本站查看
28.	何文昌，张克恭，赵凡惠，郭芮杉，高禄化，黄长形，王临旭. 290例药物性肝损伤患者临床特征分析. 实用肝脏病杂志. 2020(04): 540-543 . 百度学术
29.	李梁，陶应敏，张学敏，谢娟，陈园. 药物性肝损伤患者外周血清HIF1α和COX-2定量检测的临床价值. 肝脏. 2020(08): 848-852 . 百度学术
30.	李卉，张宏亮，杨天燕，黄振光，刘滔滔，韦芳. 我院125例抗结核药物不良反应报告分析. 中国医药导报. 2020(29): 151-154 . 百度学术
31.	姜正艳，郑亮. 异甘草酸镁治疗药物性肝损伤临床疗效观察. 世界最新医学信息文摘. 2019(07): 123 . 百度学术
32.	张惠娟，史祖宣，赵兰芳，高天慧，李健. 56例抗肿瘤药物致肝损伤临床特点分析. 临床肝胆病杂志. 2019(03): 574-578 . 本站查看
33.	梁栋，董晓锋，张燕，朱晓红，王建斌，刘妲妲，柳伟伟，方圆，王全楚. 98例药物性肝损伤的临床特点及诊疗体会. 肝脏. 2019(04): 389-391 . 百度学术
34.	黄波，张炜. 喜炎平注射液联合还原型谷胱甘肽治疗重症烧伤后急性肝功能损伤临床研究. 创伤与急危重病医学. 2019(03): 156-159 . 百度学术
35.	郭立杰，张海丛，叶立红，王超，杜婧，伍彦辉. 中西药所致药物性肝损伤临床及病理特点分析. 临床误诊误治. 2019(08): 28-33 . 百度学术
36.	吴宇宇，袁苏榆，孙四珍，王岁晶，丁洋. 药物性肝损伤诊断治疗进展概述. 药物流行病学杂志. 2018(08): 550-555 . 百度学术
37.	王建青，叶珺，郜玉峰，杨利琦. 106例药物性肝损伤患者用药回顾性调查. 中国医院药学杂志. 2018(18): 1967-1970 . 百度学术